Research ExplorerJournalsLANCET HAEMATOL Publications

LANCET HAEMATOL

1 - 34 out of 34Page size: 50

Publications

  1. 2024

  2. Methodological challenges in the development of endpoints for myelofibrosis clinical trials

    Barosi, G., Tefferi, A., Gangat, N., Szuber, N., Rambaldi, A., Odenike, O., Kröger, N., Gagelmann, N., Talpaz, M., Kantarjian, H. & Gale, R. P., 05.2024, In: LANCET HAEMATOL. 11, 5, p. e383-e389

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  3. High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial

    Schorb, E., Isbell, L. K., Kerkhoff, A., Mathas, S., Braulke, F., Egerer, G., Röth, A., Schliffke, S., Borchmann, P., Brunnberg, U., Kroschinsky, F., Möhle, R., Rank, A., Wellnitz, D., Kasenda, B., Pospiech, L., Wendler, J., Scherer, F., Deckert, M., Henkes, E., von Gottberg, P., Gmehlin, D., Backenstraß, M., Jensch, A., Burger-Martin, E., Grishina, O., Fricker, H., Malenica, N., Orbán, A., Duyster, J., Ihorst, G., Finke, J. & Illerhaus, G., 03.2024, In: LANCET HAEMATOL. 11, 3, p. e196-e205

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  4. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial

    Mai, E. K., Goldschmid, H., Miah, K., Bertsch, U., Besemer, B., Hänel, M., Krzykalla, J., Fenk, R., Schlenzka, J., Munder, M., Dürig, J., Blau, I. W., Huhn, S., Hose, D., Jauch, A., Kunz, C., Mann, C., Weinhold, N., Scheid, C., Schroers, R., von Metzler, I., Schieferdecker, A., Thomalla, J., Reimer, P., Mahlberg, R., Graeven, U., Kremers, S., Martens, U. M., Kunz, C., Hensel, M., Benner, A., Seidel-Glätzer, A., Weisel, K. C., Raab, M. S., Salwender, H. J. & German-speaking Myeloma Multicenter Group (GMMG) HD6 investigators, 02.2024, In: LANCET HAEMATOL. 11, 2, p. e101-e113

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  5. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation

    Penack, O., Marchetti, M., Aljurf, M., Arat, M., Bonifazi, F., Duarte, R. F., Giebel, S., Greinix, H., Hazenberg, M. D., Kröger, N., Mielke, S., Mohty, M., Nagler, A., Passweg, J., Patriarca, F., Ruutu, T., Schoemans, H., Solano, C., Vrhovac, R., Wolff, D., Zeiser, R., Sureda, A. & Peric, Z., 02.2024, In: LANCET HAEMATOL. 11, 2, p. e147-e159 13 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  6. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group

    Kröger, N., Bacigalupo, A., Barbui, T., Ditschkowski, M., Gagelmann, N., Griesshammer, M., Gupta, V., Hamad, N., Harrison, C., Hernandez-Boluda, J. C., Koschmieder, S., Jain, T., Mascarenhas, J., Mesa, R., Popat, U. R., Passamonti, F., Polverelli, N., Rambaldi, A., Robin, M., Salit, R. B., Scott, B. L., Tamari, R., Tefferi, A., Vannucchi, A. M., McLornan, D. P. & Barosi, G., 01.2024, In: LANCET HAEMATOL. 11, 1, p. e62-e74

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  7. 2023

  8. Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study

    Tiede, A., Hart, C., Knöbl, P., Greil, R., Oldenburg, J., Sachs, U. J., Miesbach, W., Pfrepper, C., Trautmann-Grill, K., Holstein, K., Pilch, J., Möhnle, P., Schindler, C., Weigt, C., Schipp, D., May, M., Dobbelstein, C., Pelzer, F. J., Werwitzke, S. & Klamroth, R., 11.2023, In: LANCET HAEMATOL. 10, 11, p. e913-e921

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  9. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study

    Dimopoulos, M. A., Hungria, V. T. M., Radinoff, A., Delimpasi, S., Mikala, G., Masszi, T., Li, J., Capra, M., Maiolino, A., Pappa, V., Chraniuk, D., Osipov, I., Leleu, X., Low, M., Matsumoto, M., Sule, N., Li, M., McKeown, A., He, W., Bright, S., Currie, B., Perera, S., Boyle, J., Roy-Ghanta, S., Opalinska, J. & Weisel, K., 10.2023, In: LANCET HAEMATOL. 10, 10, p. e801-e812

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  10. Inequalities in the career pathway for paediatric HSCT and cellular therapy physicians

    Gurnari, C., Spadea, M., Muratori, R., Jimenez, V., Radici, V., Torrado, S., Desai, N., Ropero, J., Muhsen, I. N., Ibrahimova, A., Du Toit, J., Hendricks, C. L., Gagelmann, N. & Horga, C., 07.2023, In: LANCET HAEMATOL. 10, 7, p. e492-e494

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  11. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial

    Döhner, H., Weber, D., Krzykalla, J., Fiedler, W., Kühn, M. W. M., Schroeder, T., Mayer, K., Lübbert, M., Wattad, M., Götze, K., Fransecky, L., Koller, E., Wulf, G., Schleicher, J., Ringhoffer, M., Greil, R., Hertenstein, B., Krauter, J., Martens, U. M., Nachbaur, D., Samra, M. A., Machherndl-Spandl, S., Basara, N., Leis, C., Schrade, A., Kapp-Schwoerer, S., Cocciardi, S., Bullinger, L., Thol, F., Heuser, M., Paschka, P., Gaidzik, V. I., Saadati, M., Benner, A., Schlenk, R. F., Döhner, K., Ganser, A. & German–Austrian AML Study Group, 07.2023, In: LANCET HAEMATOL. 10, 7, p. e495-e509

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  12. Long-term sequelae after immunotherapeutic approaches in haematological malignancies-what do we know?

    Escherich, G. & Hough, R., 06.2023, In: LANCET HAEMATOL. 10, 6, p. e395-e396

    Research output: SCORING: Contribution to journal › Comment/debate › Research

  13. Improving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma

    Beishuizen, A., Mellgren, K., Andrés, M., Auperin, A., Bacon, C. M., Bomken, S., Burke, G. A. A., Burkhardt, B., Brugieres, L., Chiang, A. K. S., Damm-Welk, C., d'Amore, E., Horibe, K., Kabickova, E., Khanam, T., Kontny, U., Klapper, W., Lamant, L., Le Deley, M-C., Loeffen, J., Macintyre, E., Mann, G., Meyer-Wentrup, F., Michgehl, U., Minard-Colin, V., Mussolin, L., Oschlies, I., Patte, C., Pillon, M., Reiter, A., Rigaud, C., Roncery, L., Salaverria, I., Simonitsch-Klupp, I., Uyttebroeck, A., Verdu-Amoros, J., Williams, D., Woessmann, W., Wotherspoon, A., Wrobel, G., Zimmermann, M., Attarbaschi, A., Turner, S. D. & European Intergroup for Childhood Non-Hodgkin Lymphoma, 03.2023, In: LANCET HAEMATOL. 10, 3, p. e213-e224 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  14. GPRC5D-targeting chimeric antigen receptors: a new treatment for multiple myeloma?

    Gagelmann, N. & Brudno, J., 02.2023, In: LANCET HAEMATOL. 10, 2, p. e82-e83

    Research output: SCORING: Contribution to journal › Comment/debate › Research

  15. Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT

    Polverelli, N., Hernández-Boluda, J. C., Czerw, T., Barbui, T., D'Adda, M., Deeg, H. J., Ditschkowski, M., Harrison, C., Kröger, N. M., Mesa, R., Passamonti, F., Palandri, F., Pemmaraju, N., Popat, U., Rondelli, D., Vannucchi, A. M., Verstovsek, S., Robin, M., Colecchia, A., Grazioli, L., Damiani, E., Russo, D., Brady, J., Patch, D., Blamek, S., Damaj, G. L., Hayden, P., McLornan, D. P. & Yakoub-Agha, I., 01.2023, In: LANCET HAEMATOL. 10, 1, p. e59-e70

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  16. 2022

  17. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

    Goldschmidt, H., Mai, E. K., Bertsch, U., Fenk, R., Nievergall, E., Tichy, D., Besemer, B., Dürig, J., Schroers, R., von Metzler, I., Hänel, M., Mann, C., Asemissen, A. M., Heilmeier, B., Weinhold, N., Huhn, S., Kriegsmann, K., Luntz, S. P., Holderried, T. A. W., Trautmann-Grill, K., Gezer, D., Klaiber-Hakimi, M., Müller, M., Khandanpour, C., Knauf, W., Scheid, C., Munder, M., Geer, T., Riesenberg, H., Thomalla, J., Hoffmann, M., Raab, M. S., Salwender, H. J., Weisel, K. C. & German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators, 11.2022, In: LANCET HAEMATOL. 9, 11, p. e810-e821

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  18. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

    Lonial, S., Popat, R., Hulin, C., Jagannath, S., Oriol, A., Richardson, P. G., Facon, T., Weisel, K., Larsen, J. T., Minnema, M. C., Abdallah, A-O., Badros, A. Z., Knop, S., Stadtmauer, E. A., Cheng, Y., Amatangelo, M., Chen, M., Nguyen, T. V., Amin, A., Peluso, T. & van de Donk, N. W. C. J., 11.2022, In: LANCET HAEMATOL. 9, 11, p. e822-e832

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  19. Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper

    Gagelmann, N., Sureda, A., Montoto, S., Murray, J., Bolaños, N., Kenyon, M., Beksac, M., Schönland, S., Hayden, P., Scheurer, H., Morgan, K., Garderet, L., McLornan, D. P. & Ruggeri, A., 10.2022, In: LANCET HAEMATOL. 9, 10, p. e786-e795

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  20. Global effort to evacuate Ukrainian children with cancer and blood disorders who have been affected by war

    Agulnik, A., Kizyma, R., Salek, M., Wlodarski, M. W., Pogorelyy, M., Oszer, A., Yakimkova, T., Nogovitsyna, Y., Dutkiewicz, M., Dalle, J-H., Dirksen, U., Eggert, A., Fernández-Teijeiro, A., Greiner, J., Kraal, K., Mueller, A., Sramkova, L., Zecca, M., Wise, P. H., Mlynarski, W. & SAFER Ukraine Collaborative, 09.2022, In: LANCET HAEMATOL. 9, 9, p. e645-e647

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  21. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

    Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., Magen, H., Larocca, A., Laubach, J. P., Petrucci, M. T., Reece, D., White, D., Mateos, M-V., Špička, I., Lazaroiu, M., Berdeja, J., Kaufman, J. L., Jou, Y-M., Ganetsky, A., Popa McKiver, M., Lonial, S., Weisel, K. & ELOQUENT-1 investigators, 06.2022, In: LANCET HAEMATOL. 9, 6, p. e403-e414

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  22. Recognising inequalities in haematopoietic stem-cell transplantation and cellular therapy training

    Horgan, C., Serroukh, Y., Gjærde, L. K., Gagelmann, N. & EBMT Trainee Committee, 05.2022, In: LANCET HAEMATOL. 9, 5, p. e323-e324

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  23. 2021

  24. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

    Ludwig, H., Sonneveld, P., Facon, T., San-Miguel, J., Avet-Loiseau, H., Mohty, M., Mateos, M-V., Moreau, P., Cavo, M., Pawlyn, C., Zweegman, S., Engelhardt, M., Driessen, C., Cook, G., Dimopoulos, M. A., Gay, F., Einsele, H., Delforge, M., Caers, J., Weisel, K., Jackson, G., Garderet, L., van de Donk, N., Leleu, X., Goldschmidt, H., Beksac, M., Nijhof, I., Schreder, M., Abildgaard, N., Hajek, R., Zojer, N., Kastritis, E., Broijl, A., Schjesvold, F., Boccadoro, M. & Terpos, E., 12.2021, In: LANCET HAEMATOL. 8, 12, p. e934-e946

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  25. Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study

    Michels, N., Boer, J. M., Enshaei, A., Sutton, R., Heyman, M., Ebert, S., Fiocco, M., de Groot-Kruseman, H. A., van der Velden, V. H. J., Barbany, G., Escherich, G., Vora, A., Trahair, T., Dalla-Pozza, L., Pieters, R., Zur Stadt, U., Schmiegelow, K., Moorman, A. V., Zwaan, C. M. & den Boer, M. L., 10.2021, In: LANCET HAEMATOL. 8, 10, p. e700-e710

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  26. Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia

    Andrés-Jensen, L., Attarbaschi, A., Bardi, E., Barzilai-Birenboim, S., Bhojwani, D., Hagleitner, M. M., Halsey, C., Harila-Saari, A., van Litsenburg, R. R. L., Hudson, M. M., Jeha, S., Kato, M., Kremer, L., Mlynarski, W., Möricke, A., Pieters, R., Piette, C., Raetz, E., Ronceray, L., Toro, C., Grazia Valsecchi, M., Vrooman, L. M., Weinreb, S., Winick, N., Schmiegelow, K. & Ponte di Legno Severe Toxicity Working Group, 07.2021, In: LANCET HAEMATOL. 8, 7, p. e513-e523 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  27. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era. a multicentre, retrospective, cohort study

    den Boer, M. L., Cario, G., Moorman, A. V., Boer, J. M., de Groot-Kruseman, H. A., Fiocco, M., Escherich, G., Imamura, T., Yeoh, A., Sutton, R., Dalla-Pozza, L., Kiyokawa, N., Schrappe, M., Roberts, K. G., Mullighan, C. G., Hunger, S. P., Vora, A., Attarbaschi, A., Zaliova, M., Elitzur, S., Cazzaniga, G., Biondi, A., Loh, M. L., Pieters, R. & Ponte di Legno Childhood ALL Working Group, 01.2021, In: LANCET HAEMATOL. 8, 1, p. e55-e66

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  28. 2020

  29. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial

    Raab, M. S., Engelhardt, M., Blank, A., Goldschmidt, H., Agis, H., Blau, I. W., Einsele, H., Ferstl, B., Schub, N., Röllig, C., Weisel, K., Winderlich, M., Griese, J., Härtle, S., Weirather, J., Jarutat, T., Peschel, C. & Chatterjee, M., 05.2020, In: LANCET HAEMATOL. 7, 5, p. e381-e394

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  30. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation

    Penack, O., Marchetti, M., Ruutu, T., Aljurf, M., Bacigalupo, A., Bonifazi, F., Ciceri, F., Cornelissen, J., Malladi, R., Duarte, R. F., Giebel, S., Greinix, H., Holler, E., Lawitschka, A., Mielke, S., Mohty, M., Arat, M., Nagler, A., Passweg, J., Schoemans, H., Socié, G., Solano, C., Vrhovac, R., Zeiser, R., Kröger, N. & Basak, G. W., 02.2020, In: LANCET HAEMATOL. 7, 2, p. e157-e167

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  31. 2019

  32. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis

    Shouval, R., Fein, J. A., Labopin, M., Kröger, N., Duarte, R. F., Bader, P., Chabannon, C., Kuball, J., Basak, G. W., Dufour, C., Galimard, J-E., Polge, E., Lankester, A., Montoto, S., Snowden, J. A., Styczynski, J., Yakoub-Agha, I., Mohty, M. & Nagler, A., 11.2019, In: LANCET HAEMATOL. 6, 11, p. e573-e584

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  33. High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial

    Hutchison, C. A., Cockwell, P., Moroz, V., Bradwell, A. R., Fifer, L., Gillmore, J. D., Jesky, M. D., Storr, M., Wessels, J., Winearls, C. G., Weisel, K., Heyne, N. & Cook, M., 04.2019, In: LANCET HAEMATOL. 6, 4, p. e217-e228

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  34. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study

    Bonifazi, F., Solano, C., Wolschke, C., Sessa, M., Patriarca, F., Zallio, F., Nagler, A., Selleri, C., Risitano, A. M., Messina, G., Bethge, W., Herrera, P., Sureda, A., Carella, A. M., Cimminiello, M., Guidi, S., Finke, J., Sorasio, R., Ferra, C., Sierra, J., Russo, D., Benedetti, E., Milone, G., Benedetti, F., Heinzelmann, M., Pastore, D., Jurado, M., Terruzzi, E., Narni, F., Völp, A., Ayuk, F., Ruutu, T. & Kröger, N., 02.2019, In: LANCET HAEMATOL. 6, 2, p. e89-e99

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  35. 2018

  36. Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial

    Biondi, A., Gandemer, V., De Lorenzo, P., Cario, G., Campbell, M., Castor, A., Pieters, R., Baruchel, A., Vora, A., Leoni, V., Stary, J., Escherich, G., Li, C-K., Cazzaniga, G., Cavé, H., Bradtke, J., Conter, V., Saha, V., Schrappe, M. & Grazia Valsecchi, M., 12.2018, In: LANCET HAEMATOL. 5, 12, p. e641-e652

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  37. 2017

  38. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial

    Ferreri, A. J. M., Cwynarski, K., Pulczynski, E., Fox, C. P., Schorb, E., La Rosée, P., Binder, M., Fabbri, A., Torri, V., Minacapelli, E., Falautano, M., Ilariucci, F., Ambrosetti, A., Roth, A., Hemmaway, C., Johnson, P., Linton, K. M., Pukrop, T., Sønderskov Gørløv, J., Balzarotti, M., Hess, G., Keller, U., Stilgenbauer, S., Panse, J., Tucci, A., Orsucci, L., Pisani, F., Levis, A., Krause, S. W., Schmoll, H. J., Hertenstein, B., Rummel, M., Smith, J., Pfreundschuh, M., Cabras, G., Angrilli, F., Ponzoni, M., Deckert, M., Politi, L. S., Finke, J., Reni, M., Cavalli, F., Zucca, E., Illerhaus, G. & International Extranodal Lymphoma Study Group (IELSG), 11.2017, In: LANCET HAEMATOL. 4, 11, p. e510-e523

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  39. 2016

  40. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial

    Illerhaus, G., Kasenda, B., Ihorst, G., Egerer, G., Lamprecht, M., Keller, U., Wolf, H-H., Hirt, C., Stilgenbauer, S., Binder, M., Hau, P., Edinger, M., Frickhofen, N., Bentz, M., Möhle, R., Röth, A., Pfreundschuh, M., von Baumgarten, L., Deckert, M., Hader, C., Fricker, H., Valk, E., Schorb, E., Fritsch, K. & Finke, J., 08.2016, In: LANCET HAEMATOL. 3, 8, p. e388-97

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  41. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

    Ferreri, A. J. M., Cwynarski, K., Pulczynski, E., Ponzoni, M., Deckert, M., Politi, L. S., Torri, V., Fox, C. P., Rosée, P. L., Schorb, E., Ambrosetti, A., Roth, A., Hemmaway, C., Ferrari, A., Linton, K. M., Rudà, R., Binder, M., Pukrop, T., Balzarotti, M., Fabbri, A., Johnson, P., Gørløv, J. S., Hess, G., Panse, J., Pisani, F., Tucci, A., Stilgenbauer, S., Hertenstein, B., Keller, U., Krause, S. W., Levis, A., Schmoll, H. J., Cavalli, F., Finke, J., Reni, M., Zucca, E., Illerhaus, G. & International Extranodal Lymphoma Study Group (IELSG), 05.2016, In: LANCET HAEMATOL. 3, 5, p. e217-27

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  42. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA), a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial

    Weishaupt, C., Strölin, A., Kahle, B., Kreuter, A., Schneider, S. W., Gerss, J., Eveslage, M., Drabik, A. & Goerge, T., 02.2016, In: LANCET HAEMATOL. 3, 2, p. e72-9

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  43. 2015

  44. Out of the haemophagocytic lymphohistiocytosis niche

    Lehmberg, K., 12.2015, In: LANCET HAEMATOL. 2, 12, p. e508-9

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research